Inhibiting a protein known as KLHL42 may ease lung fibrosis (scarring) associated with systemic scleroderma (SSc), according to a recent study. The findings were published in an article, “Kelch-like protein 42 is a pro-fibrotic ubiquitin E3 ligase involved in in systemic sclerosis,” in the Journal…
News
Starting a 501(c)(3) tax-exempt nonprofit isn’t easy, but the National Organization for Rare Disorders gave a few tips for those  looking to begin the complex process in its Feb. 20 webinar. William Whitman…
A statistical model applied to a widely used measure of skin thickening in people newly diagnosed with systemic sclerosis (SSc) identified five classes that may predict organ involvement and survival rates. Using these predictive classes — based on the…
The types of autoantibodies a person has are a better predictor of scleroderma prognosis than whether the person has other connective tissue diseases, a study reports. The study, “Clinical characteristics and survival in systemic sclerosis-mixed connective tissue disease and systemic sclerosis-overlap syndrome,” was published in the journal…
A pre-clinical stage preceding the development of digital ulcers could provide a window of opportunity for treatment before serious tissue damage occurs in people with scleroderma, according to a new study. The study was summarized in a letter to the editor titled, “Patient experiences of digital ulcer development…
An abundance of events are afoot around the world to mark Rare Disease Day 2020 on Feb. 29. The activities are focused on heightening awareness about rare diseases and the hundreds of millions of individuals they are thought to affect. Patients, caregivers, and advocates worldwide will sport denim ribbons…
A long RNA molecule called HOTAIR is produced in excess in people with scleroderma and controls the activation of myofibroblasts, key cells in the progression of this disease, according to a study. The finding expands the understanding of how to target biological drivers of scleroderma, and offers a potential…
Changes in four DNA spots influence the risk of developing both scleroderma and Crohn’s disease, researches found. One of the spots hadn’t previously been associated with either disease. The variants had opposing effects in susceptibility, “thus highlighting the complex effects that shared associations have on disease outcomes,” the…
Privigen — an approved therapy for a range of immune-related conditions — has been granted orphan drug designation by the U.S. Food and Drug Administration (FDA) for the treatment of systemic scleroderma. Orphan drug designation is given to investigational therapies with the potential to be safe and effective…
Researchers have come up with a new, patient-reported questionnaire to measure the impact of digital ulcers on hand function in people with scleroderma. The questionnaire, “Hand Disability in Systemic Sclerosis-Digital Ulcers (HDISS-DU),” was developed using patient interviews and trial data. It can be useful in evaluating the…
Recent Posts
- Dexamethasone reduces inflammation, scarring in SSc mouse model: Study
- Survival improves for SSc-PAH patients on combination therapy
- Combination drug therapy boosts lung, skin health in SSc patients
- On choosing medicine’s side effects over scleroderma progression
- Telerehabilitation improves hand mobility in scleroderma women
- Molecular pathway ID’d as key driver of scarring in scleroderma
- Limited hand function disrupts daily life for people living with SSc
- Coping with loss is part of living with scleroderma
- CAR T-cell therapy eases SSc symptoms, early trial data show
- Milk-derived particles may offer treatment path for SSc fibrosis